These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy]. Malý J; Pecka M; Gregor J; Dulícek P; Blazek M; Malý R; Pudil R; Bláha M Cas Lek Cesk; 2005; 144 Suppl 3():23-9. PubMed ID: 16335259 [TBL] [Abstract][Full Text] [Related]
3. Aspirin failure course during exercise and its connection with soluble CD40L. Kuliczkowski W; Kobusiak-Prokopowicz M; Prajs I; Karolko B; Mazurek W Thromb Res; 2007; 119(6):679-86. PubMed ID: 16780932 [TBL] [Abstract][Full Text] [Related]
4. Factors responsible for "aspirin resistance" - can we identify them? Postuła M; Tarchalska-Kryńska B; Filipiak KJ; Kosior D; Serafin A; Huczek Z; Opolski G Kardiol Pol; 2010 Apr; 68(4):403-11; discussion 412-3. PubMed ID: 20425699 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955 [TBL] [Abstract][Full Text] [Related]
7. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery. Bach J; Kammerer I; Isgro F; Haubelt H; Vogt A; Saggau W; Hellstern P Platelets; 2009 May; 20(3):150-7. PubMed ID: 19437331 [TBL] [Abstract][Full Text] [Related]
8. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Pamukcu B; Oflaz H; Onur I; Oncul A; Umman B; Koylan N; Bugra Z; Meric M; Nisanci Y Blood Coagul Fibrinolysis; 2007 Jul; 18(5):461-5. PubMed ID: 17581321 [TBL] [Abstract][Full Text] [Related]
9. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Christiaens L; Ragot S; Mergy J; Allal J; Macchi L Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of aspirin resistance measured by PFA-100. Coma-Canella I; Velasco A; Castano S Int J Cardiol; 2005 May; 101(1):71-6. PubMed ID: 15860386 [TBL] [Abstract][Full Text] [Related]
11. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Lordkipanidzé M; Pharand C; Schampaert E; Turgeon J; Palisaitis DA; Diodati JG Eur Heart J; 2007 Jul; 28(14):1702-8. PubMed ID: 17569678 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Pamukcu B; Oflaz H; Onur I; Oncul A; Ozcan M; Umman B; Mercanoglu F; Meric M; Nisanci Y Blood Coagul Fibrinolysis; 2007 Mar; 18(2):187-92. PubMed ID: 17287637 [TBL] [Abstract][Full Text] [Related]
13. Platelet aggregometric study on whole blood of patients with ischaemic heart disease. Lakhey M; Agarwal A; Badhe B Kathmandu Univ Med J (KUMJ); 2005; 3(1):11-6. PubMed ID: 16401937 [TBL] [Abstract][Full Text] [Related]
14. Screening for aspirin resistance in stable coronary artery patients by three different tests. Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317 [TBL] [Abstract][Full Text] [Related]
17. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882 [TBL] [Abstract][Full Text] [Related]
18. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Faraday N; Becker DM; Yanek LR; Herrera-Galeano JE; Segal JB; Moy TF; Bray PF; Becker LC Am J Cardiol; 2006 Sep; 98(6):774-9. PubMed ID: 16950183 [TBL] [Abstract][Full Text] [Related]
19. Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Coakley M; Self R; Marchant W; Mackie I; Mallett SV; Mythen M Anaesthesia; 2005 Dec; 60(12):1173-8. PubMed ID: 16288614 [TBL] [Abstract][Full Text] [Related]
20. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]